Subscribe to RSS
DOI: 10.1055/s-2004-831896
Inhibins, Activins, and Follistatin in the Aging Female and Male
Publication History
Publication Date:
20 August 2004 (online)
Dimeric inhibins, activins, and follistatin (FS) were all initially characterized as reproductive endocrine hormones that regulate follicle-stimulating hormone (FSH) secretion. This model, however, has expanded under the weight of current medical evidence. Activin appears to play a central auto/paracrine role in reproductive and nonreproductive tissues. Inhibin and FS each have important counterregulatory functions in activin signaling. With reproductive aging, inhibin B declines along with the follicular pool and disturbs the dynamics of the normal menstrual cycle of midreproductive age. The loss of inhibin restraint of FSH secretion appears to be the initiating endocrine event that leads to menstrual cycle shortening and some of the hormonal unpredictability of the late reproductive years. It may also be related to the decline in fertility that occurs in reproductive aging. In men, inhibin B is an excellent marker for gonadal competence, and the decline of inhibin B with age reflects decreased gonadal reserve in both sexes. Circulating activin increases with aging, but its effect on reproduction in women and men is not clear. FS does not appear to change greatly with aging in men or women. The age-related fluctuations in this delicately balanced regulatory triad influence reproductive capacity and the sequelae of chronological aging. Elucidation of the molecular pathways responsible for the action of these hormones may allow closer integration with their current conceptual roles in aging.
KEYWORDS
Inhibin - activin - follistatin - aging - reproductive aging - menopausal transition
REFERENCES
- 1 Klein N, Illingworth P, Groome M, McNeilly A, Battaglia D, Soules M. Decreased inhibin B secretion is associated with a monotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. J Clin Endocrinol Metab. 1996; 81 2742-2745
- 2 Burger H G, Dudley E C, Hopper J L et al.. The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. J Clin Endocrinol Metab. 1995; 80 3537-3545
- 3 Burger H, Cahir N, Robertson D et al.. Serum inhibins A and B fall differentially as FSH rises in perimenopausal women. Clin Endocrinol (Oxf). 1998; 48 809-813
- 4 Reame N, Wyman T, Phillips D, de Kretser D, Padmanabhan V. Net increase in stimulatory input resulting from a decrease in inhibin B and an increase in activin A may contribute in part to the rise in follicular phase FSH of aging cycling women. J Clin Endocrinol Metab. 1998; 83 3302-3307
- 5 Burger H G, Dudley E C, Hopper J L et al.. Prospectively measured levels of serum FSH, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab. 1999; 84 4025-4030
- 6 Santoro N, Adel T, Skurnick H. Decreased inhibin tone and increased activin A secretion characterize reproductive aging in women. Fertil Steril. 1999; 71 658-662
- 7 Welt C, McNicholl D, Taylor A, Hall J. Female reproductive aging is marked by decreased secretion of dimeric inhibin. J Clin Endocrinol Metab. 1999; 84 105-111
- 8 Burger H G, Dudley E C, Robertson D M, Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Horm Res. 2002; 57 257-275
- 9 MacNaughton J A, Banagh M L, McCloud P I, Burger H G. Inhibin and age in men. Clin Endocrinol (Oxf). 1991; 35 341-346
- 10 Tenover J S, Bremner W J. The effects of normal aging on the response of the pituitary-gonadal axis to chronic clomiphene administration in men. J Androl. 1991; 12 258-263
- 11 Haji M, Tanaka S, Nishi Y et al.. Sertoli cell function declines earlier than Leydig cell function in aging Japanese men. Maturitas. 1994; 18 143-153
- 12 Bohring C, Krause W. Serum levels of inhibin B in men of different age groups. Aging Male. 2003; 6 73-78
- 13 Meachem S J, Nieschlag E, Simoni M. Inhibin B in male reproduction: pathophysiology and clinical relevance. Eur J Endocrinol. 2001; 145 561-571
- 14 Mahmoud A M, Goemaere S, El-Garem Y, Van Pottelbergh I, Comhair F H, Kaufman J M. Testicular volume in relation to hormonal indices of gonadal function in community-dwelling elderly men. J Clin Endocrinol Metab. 2003; 88 179-184
- 15 Ling N, DePaolo L V, Bicsak T A, Shimasaki S. Novel ovarian regulatory peptides: inhibin, activin, and follistatin. Clin Obstet Gynecol. 1990; 33 690-702
- 16 Carroll R, Corrigan A, Gharib S, Vale W, Chin W. Inhibin, activin and follistatin: regulation of FSH messenger RNA levels. Mol Endocrinol. 1989; 3 1969-1989
- 17 Rivier C, Schwall R, Mason A, Burton L, Vaughan J, Vale W. Effect of recombinant inhibin on LH and FSH secretion in the rat. Endocrinology. 1991; 128 1548-1554
- 18 Weiss J, Crowley Jr W F, Halvorsan L M, Jameson J L. Perfusion of rat pituitary cells with gonadotropin-releasing hormone, activin, and inhibin reveals distinct effects on gonadotropin gene expression and secretion. Endocrinology. 1993; 132 2307-2311
- 19 Ying S Y. Inhibins, activins and follistatins: gonadal proteins modulating the secretion of FSH. Endocr Rev. 1988; 9 267-293
- 20 Stouffer R, Woodruff T, Dahl K, Hess D, Mather J, Molskness T. Human recombinant activin-A alters pituitary LH and FSH secretion, follicular development and steroidogenesis during the menstrual cycle in rhesus monkeys. J Clin Endocrinol Metab. 1993; 77 241-248
- 21 Schneyer A L, Rzucidlo D A, Sluss P M, Crowley Jr W F. Characterization of unique binding kinetics of follistatin and activin or inhibin in serum. Endocrinology. 1994; 135 667-674
- 22 Chapman S C, Woodruff T K. Betaglycan localization in the female rat pituitary: implications for the regulation of FSH by inhibin. Endocrinology. 2003; 144(12) 5640-5649
- 23 Weiss J, Harris P E, Halvorson L M, Crowley Jr W F, Jameson J L. Dynamic regulation of follicle-stimulating hormone-beta messenger ribonucleic acid levels by activin and gonadotropin-releasing hormone in perifused rat pituitary cells. Endocrinology. 1992; 131 1403-1408
- 24 Lewis K A, Gray P C, Blount A L et al.. Betaglycan binds inhibin and can mediate functional antagonism of activin signaling. Nature. 2000; 404 411-414
- 25 Esparza-Lopez J, Montiel J L, Vilchis-Landeros M M, Okadome T, Miyazono K, Lopez-Casillas F. Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor beta and inhibin A. J Biol Chem. 2001; 276 14588-14596
- 26 Chapman S C, Bernard D J, Jelen J, Woodruff T K. Properties of inhibin binding to betaglycan, InhBP/p120 and the activin type II receptors. Mol Cell Endocrinol. 2002; 196 79-93
- 27 Krummen L, Woodruff T, de Guzman G et al.. Identification and characterization of binding proteins for inhibin and activin in human serum and follicular fluids. Endocrinology. 1993; 132 431-443
- 28 Nakamura T, Takio K, Eto Y, Shibai H, Titani K, Sugino H. Activin-binding protein from rat ovary is follistatin. Science. 1990; 247 836-838
- 29 Klein N A, Battaglia D E, Woodruff T K et al.. Ovarian follicular concentrations of activin, follistatin, inhibin, insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-2 (IGFBP-2), IGFBP-3, and vascular endothelial growth factor in spontaneous menstrual cycles of normal women of advanced reproductive age. J Clin Endocrinol Metab. 2000; 85 4520-4525
- 30 Lin S Y, Morrison J R, Phillips D J, de Kretser D M. Regulation of ovarian function by the TGF-beta superfamily and follistatin. Reproduction. 2003; 126 133-148
- 31 Vaughan J M, Vale W W. Alpha 2-macroglobulin is a binding protein of inhibin and activin. Endocrinology. 1993; 132 2038-2050
- 32 Wrathall J H, Knight P G. Effects of inhibin-related peptides and oestradiol on androstenedione and progesterone secretion by bovine theca cells in vitro. J Endocrinol. 1995; 145 491-500
- 33 Schneyer A L, Hall H A, Lambert-Messerlian G, Wang Q F, Sluss P, Crowley Jr W F. Follistatin-activin complexes in human serum and follicular fluid differ immunologically and biochemically. Endocrinology. 1996; 137 240-247
- 34 Schwall R, Mason A, Wilcox J, Bassett S, Zeleznik A. Localization of inhibin/activin subunit mRNAs within the primate ovary. Mol Endocrinol. 1990; 4 75-79
- 35 Schneyer A L, Fujiwara T, Fox J et al.. Dynamic changes in the intrafollicular inhibin/activin/follistatin axis during human follicular development: relationship to circulating hormone concentrations. J Clin Endocrinol Metab. 2000; 85 3319-3330
- 36 McConnell D S, Wang Q, Sluss P M et al.. A two-site chemiluminescent assay for activin-free follistatin reveals that most follistatin circulating in men and normal cycling women is in an activin-bound state. J Clin Endocrinol Metab. 1998; 83 851-858
- 37 Welt C, Sidis Y, Keutmann H, Schneyer A. Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med (Maywood). 2002; 227 724-752
- 38 McLachlan R I, Robertson D M, Burger H G, de Kretser D M. The radioimmunoassay of bovine and human follicular fluid and serum inhibin. Mol Cell Endocrinol. 1986; 46 175-185
- 39 Groome N, Illingworth P, O’Brien M et al.. Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay. Clin Endocrinol (Oxf). 1994; 40 717-723
- 40 Yamoto M, Minami S, Nakano R, Kobayashi M. Immunohistochemical localization of inhibin/activin subunits in human ovarian follicles during the menstrual cycle. J Clin Endocrinol Metab. 1992; 74 989-993
- 41 Roberts V J, Barth S, El-Roiey A, Yen S SC. Expression of inhibin/activin subunits and follistatin mRNA and proteins in ovarian follicle and corpus luteum during the human menstrual cycle. J Clin Endocrinol Metab. 1993; 77 1402-1410
- 42 Muttukrishna S, Fowler P A, George L, Groome N P, Knight P G. Changes in peripheral serum levels of total activin A during the human menstrual cycle and pregnancy. J Clin Endocrinol Metab. 1996; 81 3328-3334
- 43 Vihko K K, Blauer M, Kujansuu E et al.. Activin B: detection by an immunoenzymometric assay in human serum during ovarian stimulation and late pregnancy. Hum Reprod. 1998; 13 841-846
- 44 Klein R, Findlay J K, Clarke I J, de Kretser D M, Robertson D M. Radioimmunoassay of FSH-suppressing protein in the ewe: concentrations during the oestrous cycle and following ovariectomy. J Endocrinol. 1993; 137 433-443
- 45 Gilfillan C P, Robertson D M. Development and validation of a radioimmunoassay for follistatin in human serum. Clin Endocrinol (Oxf). 1994; 41 453-461
- 46 Wang Q F, Khoury R H, Smith P C et al.. A two-site monoclonal antibody immunoradiometric assay for human follistatin: secretion by a human ovarian teratocarcinoma-derived cell line (PA-1). J Clin Endocrinol Metab. 1996; 81 1434-1441
- 47 Evans L W, Muttukrishna S, Groome N P. Development, validation and application of an ultra-sensitive two-site enzyme immunoassay for human follistatin. J Endocrinol. 1998; 156 275-282
- 48 Welt C K, Martin K A, Taylor A E et al.. Frequency modulation of follicle-stimulating hormone (FSH) during the luteal-follicular transition: evidence for FSH control of inhibin B in normal women. J Clin Endocrinol Metab. 1997; 82 2645-2652
- 49 Demura R, Suzuki T, Tajima S et al.. Human plasma free activin and inhibin levels during the menstrual cycle. J Clin Endocrinol Metab. 1993; 76 1080-1082
- 50 Khoury R H, Wang Q F, Crowley Jr W F et al.. Serum follistatin levels in women: evidence against an endocrine function of ovarian follistatin. J Clin Endocrinol Metab. 1995; 80 1361-1368
- 51 Sherman B M, West J H, Korenman S G. The menopausal transition: analysis of LH, FSH, estradiol and progesterone concentrations during menstrual cycles of older women. J Clin Endocrinol Metab. 1976; 42 629-636
- 52 Wilshire G B, Loughlin J S, Brown J R, Adel T, Santoro N. Diminished function of the somatotropic axis in older reproductive aged women. J Clin Endocrinol Metab. 1995; 80 608-613
- 53 Santoro N, Brown J R, Adel T, Skurnick J H. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab. 1996; 81 1495-1501
- 54 Lee S J, Lenton E A, Sexton L, Cooke I D. The effect of age on the cyclical patterns of plasma LH, FSH, oestradiol and progesterone in women with regular menstrual cycles. Hum Reprod. 1988; 3 851-855
- 55 Lenton E A, Landgren B, Sexton L, Harper L. Normal variation in the length of the follicular phase of the menstrual cycle: effect of chronological age. Br J Obstet Gynaecol. 1984; 91 681-684
- 56 Santoro N, Isaac B, Neal-Perry G et al.. Impaired folliculogenesis and ovulation in older reproductive aged women. J Clin Endocrinol Metab. 2003; 88 5502-5509
- 57 Danforth D R, Arborgast L K, Mroueh J et al.. Dimeric inhibin: a direct marker of ovarian aging. Fertil Steril. 1998; 70 119-123
- 58 Tong S, Wallace E M, Burger H G. Inhibins and activins: clinical advances in reproductive medicine. Clin Endocrinol (Oxf). 2003; 58 115-127
- 59 Welt C K, Smith Z A, Pauler D K, Hall J E. Differential regulation of inhibin A and inhibin B by luteinizing hormone, follicle-stimulating hormone, and stage of follicle development. J Clin Endocrinol Metab. 2001; 86 2531-2537
- 60 Loria P, Petraglia F, Concari M et al.. Influence of age and sex on serum concentrations of total dimeric activin A. Eur J Endocrinol. 1998; 139 487-492
- 61 Soules M R, Sherman S, Parrott E et al.. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril. 2001; 76 874-878
- 62 Hee J, MacNaughton J, Bangah M, Burger H G. Perimenopausal patterns of gonadotrophins, immunoreactive inhibin, oestradiol and progesterone. Maturitas. 1993; 18 9-20
- 63 Tenover J S, Bremner W J. Circadian rhythm of serum immunoreactive inhibin in young and elderly men. J Gerontol. 1991; 46 M181-M184
- 64 Mahmoud A M, Goemaere S, De Bacquer D, Comhaire F H, Kaufman J M. Serum inhibin B levels in community-dwelling elderly men. Clin Endocrinol (Oxf). 2000; 53 141-147
- 65 Tenover J S, McLachlan R I, Dahl K D, Burger H G, de Kretser D M, Bremner W J. Decreased serum inhibin levels in normal elderly men: evidence for a decline in Sertoli cell function with aging. J Clin Endocrinol Metab. 1988; 67 455-459
- 66 Tenover J S, Dahl K D, Vale W W, Rivier J E, Bremner W J. Hormonal responses to a potent gonadotropin hormone-releasing hormone antagonist in normal elderly men. J Clin Endocrinol Metab. 1990; 71 881-888
- 67 Fingscheidt U, Nieschlag E. The response of inhibin to human chorionic gonadotrophin is decreased in senescent men compared with young men. J Endocrinol. 1989; 123 R9-11
- 68 Baccarelli A, Morpurgo P S, Corsi A et al.. Activin A serum levels and aging of the pituitary-gonadal axis: cross sectional study in middle aged and elderly healthy subjects. Exp Gerontol. 2001; 36 1403-1412
- 69 Harada K, Shintani Y, Sakamoto Y, Wakatsuki M, Shitsukawa K, Sait S. Serum immunoreactive activin A levels in normal subjects and patients with various diseases. J Clin Endocrinol Metab. 1996; 81 2125-2130
- 70 Woodruff T K, Lyon R J, Hansen S E, Rice G C, Mather J P. Inhibin and activin locally regulate rat ovarian folliculogenesis. Endocrinology. 1990; 127 3196-3205
- 71 Erickson G F, Kokka S, Rivier C. Activin causes premature superovulation. Endocrinology. 1995; 136 4804-4813
- 72 Findlay J K. An update on the roles of inhibin, activin, and follistatin as local regulators of folliculogenesis. Biol Reprod. 1993; 48 15-23
- 73 Cataldo N A, Rabinovici J, Fujimoto V Y, Jaffe R B. Follistatin antagonizes the effects of activin-A on steroidogenesis in human luteinizing granulosa cells. J Clin Endocrinol Metab. 1994; 79 272-277
- 74 Miro F, Hillier S G. Modulation of granulosa cell deoxyribonucleic acid synthesis and differentiation by activin. Endocrinology. 1996; 137 464-468
- 75 Yokota H, Yamada K, Liu X et al.. Paradoxical action of activin A on folliculogenesis in immature and adult mice. Endocrinology. 1997; 138 4572-4576
- 76 El-Hefnawy T, Zeleznik A J. Synergism between FSH and activin in the regulation of proliferating cell nuclear antigen (PCNA) and cyclin D2 expression in rat granulosa cells. Endocrinology. 2001; 142 4357-4362
- 77 Nakamura T, Sugino K, Titani K, Sugino H. Follistatin, an activin-binding protein, associates with heparan sulfate chains of proteoglycans on follicular granulosa cells. J Biol Chem. 1991; 266 19432-19437
- 78 Inouye S, Ling N, Shimasaki S. Localization of the heparin binding site of follistatin. Mol Cell Endocrinol. 1992; 90 1-6
- 79 Delbaere A, Sidis Y, Schneyer A L. Differential response to exogenous and endogenous activin in a human ovarian teratocarcinoma-derived cell line (PA-1): regulation by cell surface follistatin. Endocrinology. 1999; 140 2463-2470
- 80 Roberts V J, Barth S, el-Roeiy A, Yen S S. Expression of inhibin/activin system messenger ribonucleic acids and proteins in ovarian follicles from women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 1994; 79 1434-1439
- 81 Yu A W, Shao L E, Frigon Jr N L, Yu J. Detection of functional and dimeric activin A in human marrow microenvironment. Implications for the modulation of erythropoiesis. Ann N Y Acad Sci. 1994; 718 285-298
- 82 Ogawa Y, Schmidt D K, Nathan R M et al.. Bovine bone activin enhances bone morphogenetic protein-induced ectopic bone formation. J Biol Chem. 1992; 267 14233-14237
- 83 Inoue S, Nomura S, Hosoi T, Ouchi Y, Orimo H, Muramatsu M. Localization of follistatin, an activin-binding protein, in bone tissues. Calcif Tissue Int. 1994; 55 395-397
- 84 Funaba M, Ogawa K, Abe M. Expression and localization of activin receptors during endochondral bone development. Eur J Endocrinol. 2001; 144 63-71
- 85 Gaddy-Kurten D, Coker J K, Abe E, Jilka R L, Manolagas S C. Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Endocrinology. 2002; 143 74-83
- 86 Inouye S, Orimo A, Hosoi T et al.. Demonstration of activin-A in arteriosclerotic lesions. Biochem Biophys Res Commun. 1994; 205 441-448
- 87 Molloy C J, Taylor D S, Pawlowski J E. Novel cardiovascular actions of the activins. J Endocrinol. 1999; 161 179-185
- 88 Kojima I, Maeshima A, Zhang Y Q. Role of the activin-follistatin system in the morphogenesis and regeneration of the renal tubules. Mol Cell Endocrinol. 2001; 180(1-2) 179-182
- 89 Maeshima A, Shiozaki S, Tajima T, Nakazato Y, Naruse T, Kojima I. Number of glomeruli is increased in the kidney of transgenic mice expressing the truncated type II activin receptor. Biochem Biophys Res Commun. 2000; 268 445-449
- 90 Kogure K, Zhang Y Q, Kanzaki M, Omata W, Mine T, Kojima I. Intravenous administration of follistatin: delivery to the liver and effect on liver regeneration after partial hepatectomy. Hepatology. 1996; 24 361-366
- 91 Phillips D J, Jones K L, Scheerlinck J Y, Hedger M P, de Kretser D M. Evidence for activin A and follistatin involvement in the systemic inflammatory response. Mol Cell Endocrinol. 2001; 180 155-162
Nanette SantoroM.D.
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Albert Einstein College of Medicine
1300 Morris Park Avenue, Mazer 316
Bronx, NY 10461